Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw

Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF as predictive marker of B-ONJ onset. Of the 81 patients, 6 developed B-ONJ following bispho...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenzi, Bruno, Napolitano, Andrea, Zoccoli, Alice, Iuliani, Michele, Pantano, Francesco, Papapietro, Nicola, Denaro, Vincenzo, Santini, Daniele, Tonini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472182/
https://www.ncbi.nlm.nih.gov/pubmed/22986334
http://dx.doi.org/10.1186/1756-8722-5-56
Descripción
Sumario:Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF as predictive marker of B-ONJ onset. Of the 81 patients, 6 developed B-ONJ following bisphosphonate treatment. These patients showed a strongest decrease in VEGF circulating levels at day 7 and at day 21 after the first administration. These data demonstrated for the first time that the anti-angiogenic properties of bisphosphonates are directly linked to B-ONJ pathogenesis and serum VEGF levels could represent an effective early predictive marker.

Ejemplares similares